Cardiosolutions raises $7m in series A:
This article was originally published in Clinica
Heart repair specialist Cardiosolutions has secured $7m in a series A convertible preferred stock financing round. The financing, led by BioVentures Investors, will help Cardiosolutions fund the first human trials of its minimally-invasive system for treating mitral regurgitation, which are expected in 2008. The Stoughton, Massachusetts-based firm believes that its percuntaneous technologies - comprising the Spacer-Tek, the Percu-Pro, and the Mitra-Spacer - reduce patient discomfort and recovery time, as it avoids the need for open heart surgery. Mitral regurgitation is a heart valve disorder which affects approximately 6% of women and 3% of men, according to Cardiosolutions.